BACKGROUND: Chronic myeloid leukemia (CML) is a rare disease in children, distinct from its adult counterpart in terms of presentation and management. This study aims to evaluate the clinical characteristics and treatment outcomes of pediatric CML patients treated at the National Bank of Kuwait (NBK) Children Specialty Hospital in Kuwait over a decade. METHODS: A retrospective review was conducted on the medical records of children diagnosed with CML between 2010 and 2020. Data on patient demographics, clinical presentation, treatment regimens, and outcomes were collected and analyzed. RESULTS: All patients presented with leukocytosis and most had splenomegaly. Imatinib, a first-line tyrosine kinase inhibitor (TKI), achieved a good response rate, with none of the patients requiring bone marrow transplantation. Despite some patients required dose adjustments or second-line TKIs due to complications or loss of response, the overall outcomes were positive, reinforcing the efficacy of TKIs in pediatric CML. CONCLUSION: This study highlights the distinct clinical presentation and response to TKI therapy in children with CML, compared to adults. The rarity of pediatric CML presents challenges in understanding disease characteristics and optimizing treatment approaches. Further research is needed to determine optimal treatment duration for this population.